Eradication of Prostate Cancer Using RaproCell™ (F-989)
NCT01987999
1st IRB – Prostate Study Results
RaproCell™ taken for 12 months
> 60 Prostate Cancer Patients, each confirmed with biopsy
> Each Patient took RaproCell™ daily for 12 months – No surgery, chemo or radiation
> Includes Patient Reports on
- PSA Scores
- Gleason Scores
- Negative Side Effects
> Average PSA Scores dropped from 10.07 to 1.48
> Average Gleason Scores dropped from 6.45 to 0.33
- Example: A patient with an initial PSA of 54.6 and a Gleason Score of 10 now has a zero score in both categories.
> The 60 patients reported virtually no major negative side-effects
RaproCell™ use dramatically decreases Gleason score in prostate cancer patients
RaproCell™ Clinical Trial PSA Scores
RaproCell™ use dramatically decreases PSA score in prostate cancer patients
RaproCell™ Clinical Trial Gleason Scores
